

Hemophilia A

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Trial Status
Completed

Trial Runs In
24 Countries

Trial Identifier
NCT03191799 2016-004366-25,
STASEY MO39129

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03191799 2016-004366-25, STASEY MO39129
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 12 Years

Healthy Volunteers
No